Moreover, the 36-month beta value for MREO is 0.96. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MREO is 140.60M and currently, short sellers hold a 3.23% of that float. On August 30, 2024, MREO’s average trading volume was 1.16M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MREO) stock’s latest price update
Mereo Biopharma Group Plc ADR (NASDAQ: MREO)’s stock price has dropped by -1.93 in relation to previous closing price of 4.67. Nevertheless, the company has seen a gain of 1.55% in its stock price over the last five trading days. globenewswire.com reported 2024-08-13 that Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $87.4 million as of June 30, 2024, which includes the net proceeds of the Company’s $50 million registered direct offering in June 2024.
MREO’s Market Performance
MREO’s stock has risen by 1.55% in the past week, with a monthly rise of 12.81% and a quarterly rise of 27.58%. The volatility ratio for the week is 5.40% while the volatility levels for the last 30 days are 6.34% for Mereo Biopharma Group Plc ADR. The simple moving average for the past 20 days is 9.37% for MREO’s stock, with a 40.50% simple moving average for the past 200 days.
Analysts’ Opinion of MREO
Many brokerage firms have already submitted their reports for MREO stocks, with Robert W. Baird repeating the rating for MREO by listing it as a “Outperform.” The predicted price for MREO in the upcoming period, according to Robert W. Baird is $8 based on the research report published on June 13, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see MREO reach a price target of $4. The rating they have provided for MREO stocks is “Buy” according to the report published on October 13th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to MREO, setting the target price at $4 in the report published on August 12th of the previous year.
MREO Trading at 14.82% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.76% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 5.40%.
During the last 5 trading sessions, MREO rose by +1.55%, in comparison to the 20-day moving average. In addition, Mereo Biopharma Group Plc ADR saw 98.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MREO starting from PAKIANATHAN DEEPIKA, who sale 105,244 shares at the price of $4.43 back on Aug 22 ’24. After this action, PAKIANATHAN DEEPIKA now owns 0 shares of Mereo Biopharma Group Plc ADR, valued at $466,210 using the latest closing price.
Deepika Pakianathan, the Director of Mereo Biopharma Group Plc ADR, proposed sale 105,244 shares at $4.43 during a trade that took place back on Aug 22 ’24, which means that Deepika Pakianathan is holding shares at $466,210 based on the most recent closing price.
Stock Fundamentals for MREO
Current profitability levels for the company are sitting at:
- -38.66 for the present operating margin
- -0.03 for the gross margin
The net margin for Mereo Biopharma Group Plc ADR stands at -37.81. The total capital return value is set at -0.43. Equity return is now at value -39.59, with -26.75 for asset returns.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.33. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 7.08.
Currently, EBITDA for the company is -23.95 million with net debt to EBITDA at 2.39. When we switch over and look at the enterprise to sales, we see a ratio of 696.42. The receivables turnover for the company is 0.33for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.07.
Conclusion
To wrap up, the performance of Mereo Biopharma Group Plc ADR (MREO) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
